PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33845103-11 2021 Cisplatin suppressed BDNF in the hippocampus while increased IL-1beta and TNF-alpha. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 74-83 33548025-6 2021 Cisplatin resulted in a significant increase in lipid peroxidation, nitric oxide (NO), and TNF-alpha and a significant decrease in reduced glutathione (GSH) levels and Na+, K+- ATPase activity. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 91-100 33216283-9 2021 Proinflammatory cytokines (IL-1beta and TNF-alpha) and metalloproteinase-2 and 9 (MMP-2/9) were increased by cisplatin treatment. Cisplatin 109-118 tumor necrosis factor Rattus norvegicus 40-49 33297925-7 2021 RESULTS: Administration of CDDP single dose (7.5 mg/kg IP) 5 days before the end of the experiment (at day 23) produced a significant decrease in renal glutathione levels and a significant increase in serum urea nitrogen, creatinine, renal malondialdehyde, tumor necrosis factor-alpha, tumor suppressor protein (p53) and nuclear factor kappa B levels compared to the control group. Cisplatin 27-31 tumor necrosis factor Rattus norvegicus 257-284 33443844-9 2021 RESULTS: Compared with individual CDDP or CNPs treatments, the combined CDDP + CNPs treatment elevated significantly the coagulation function, relative heart weight, and troponin I, lactate dehydrogenase, interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and total nitric oxide levels in the plasma. Cisplatin 72-76 tumor necrosis factor Rattus norvegicus 227-254 33443844-9 2021 RESULTS: Compared with individual CDDP or CNPs treatments, the combined CDDP + CNPs treatment elevated significantly the coagulation function, relative heart weight, and troponin I, lactate dehydrogenase, interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and total nitric oxide levels in the plasma. Cisplatin 72-76 tumor necrosis factor Rattus norvegicus 256-264 33443844-10 2021 In heart homogenates, the combination of CDDP and CNPs induced a significant increase in IL-6, TNFalpha, catalase, and glutathione. Cisplatin 41-45 tumor necrosis factor Rattus norvegicus 95-103 33381027-7 2020 Also, the tissue levels of the pro-inflammatory mediators; IL-1beta, TNF-alpha, and NF-kB, were significantly increased in the cisplatin group. Cisplatin 127-136 tumor necrosis factor Rattus norvegicus 69-78 31878169-10 2019 Myricetin also attenuated deteriorative effects induced by cisplatin by regulating the level of molecular markers of inflammation (NF-kappaB, Nrf-2, IL-6, and TNF-alpha), restoring Nrf-2 levels, and controlling goblet cell disintegration. Cisplatin 59-68 tumor necrosis factor Rattus norvegicus 159-168 32711445-9 2020 RESULTS: Administration of L-arginine to cisplatin-treated rats induced significant decrease in the average ABR threshold shifts at all frequencies, tissue TGF-beta1, TNF-alpha and IL-15 associated with significant increase in tissue antioxidant enzymes, total nitrate/nitrite and Nrf2/HO-1 content compared to cisplatin group. Cisplatin 41-50 tumor necrosis factor Rattus norvegicus 167-176 30604648-6 2019 Furthermore, cisplatin treated animals exhibited a noticeable pro-inflammatory response with the substantial increase in renal levels of TNF-alpha, IL-1beta, and IL-6 and decrease in the renal level of IL-10. Cisplatin 13-22 tumor necrosis factor Rattus norvegicus 137-146 31590115-6 2019 Cisplatin increased the inflammatory mediators; nitrite and tumor necrosis factor-alpha (TNF- alpha) in hepatic tissues. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 60-87 31590115-6 2019 Cisplatin increased the inflammatory mediators; nitrite and tumor necrosis factor-alpha (TNF- alpha) in hepatic tissues. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 89-99 30911969-4 2019 The administration of CDDP induced marked body weight loss and renal damage, manifested by significant increases (p < 0.05) in serum creatinine, urea, and uric acid levels and significant reductions in serum Na, Ca, and phosphorus concentrations, in addition to severe alterations in serum and renal tissue levels of tumor necrosis factor-alpha in comparison with control rats. Cisplatin 22-26 tumor necrosis factor Rattus norvegicus 320-347 29945277-8 2019 Also, cisplatin increased ERK1/2 phosphorylation and NF-kappaB expression, which subsequently increased mRNA expression of TNF-alpha, IL-6, KIM-1, NGAL, and Bax/Bcl-2 ratio as well as decreased mRNA expression of IL-10 in kidney tissues. Cisplatin 6-15 tumor necrosis factor Rattus norvegicus 123-132 31103702-7 2019 Additionally, cisplatin-injected rats showed a significant rise in tissue levels of IL-1beta, TNF-alpha, NF-kB, and caspase-3 enzymatic activity. Cisplatin 14-23 tumor necrosis factor Rattus norvegicus 94-103 30893507-9 2019 Cisplatin upregulates cytokines (i.e., TNF-alpha and IL-1beta) and NF-kappaB, and downregulates Nrf2 and HO-1. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 39-48 30929167-5 2019 Compared to normal control rats, CDDP-injected rats showed significantly (p < 0.05) higher serum levels of renal injury biomarkers (uric acid, urea, and creatinine) and tumor necrosis factor-alpha (TNF-alpha), as well as increased renal tissue concentrations of malondialdehyde, nitric oxide, and TNF-alpha. Cisplatin 33-37 tumor necrosis factor Rattus norvegicus 172-199 30929167-5 2019 Compared to normal control rats, CDDP-injected rats showed significantly (p < 0.05) higher serum levels of renal injury biomarkers (uric acid, urea, and creatinine) and tumor necrosis factor-alpha (TNF-alpha), as well as increased renal tissue concentrations of malondialdehyde, nitric oxide, and TNF-alpha. Cisplatin 33-37 tumor necrosis factor Rattus norvegicus 201-210 30929167-5 2019 Compared to normal control rats, CDDP-injected rats showed significantly (p < 0.05) higher serum levels of renal injury biomarkers (uric acid, urea, and creatinine) and tumor necrosis factor-alpha (TNF-alpha), as well as increased renal tissue concentrations of malondialdehyde, nitric oxide, and TNF-alpha. Cisplatin 33-37 tumor necrosis factor Rattus norvegicus 300-309 31043768-8 2019 Moreover, CDDP enhanced the synthesis of pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6. Cisplatin 10-14 tumor necrosis factor Rattus norvegicus 76-103 29339643-11 2017 In group 3, RIPC reversed immunostaining for tumor necrosis factor-alpha and inducible nitric oxide synthase in the stria vascularis injured by cisplatin (p < 0.05). Cisplatin 144-153 tumor necrosis factor Rattus norvegicus 45-72 31692421-6 2019 In addition, administration of inhibitors to IL-1beta, IL-6 and TNF-alpha attenuated amplification of GAT-1 and GAT-3 and improved hearing impairment induced by cisplatin. Cisplatin 161-170 tumor necrosis factor Rattus norvegicus 64-73 30201375-9 2018 These treatments suppressed elevated renal plasma norepinephrine, TNF-alpha, MCP-1 and cleaved caspase 3 expressions which occurred after administration of cisplatin. Cisplatin 156-165 tumor necrosis factor Rattus norvegicus 66-75 30152807-6 2018 RESULTS: CP group administered cisplatin had significantly increased blood, serum, and cardiac tissue malondialdehyde (MDA), interleukin 1 beta (IL-1ss), tumor necrosis factor alpha (TNF-alpha), troponin I, creatine kinase (CK), and CK-MB levels compared to the HE group, whereas there was a significant decrease in the total glutathione (tGSH) levels. Cisplatin 31-40 tumor necrosis factor Rattus norvegicus 154-181 30152807-6 2018 RESULTS: CP group administered cisplatin had significantly increased blood, serum, and cardiac tissue malondialdehyde (MDA), interleukin 1 beta (IL-1ss), tumor necrosis factor alpha (TNF-alpha), troponin I, creatine kinase (CK), and CK-MB levels compared to the HE group, whereas there was a significant decrease in the total glutathione (tGSH) levels. Cisplatin 31-40 tumor necrosis factor Rattus norvegicus 183-192 29455557-7 2018 Regarding these parameters, in CIS group MDA, MPO, IL1beta and TNF-alpha levels were statistically significantly increased with cisplatin administration and giving rutin concomitantly with cisplatin prevented this increase. Cisplatin 128-137 tumor necrosis factor Rattus norvegicus 63-72 30021657-8 2018 RESULTS: Cisplatin injection showed a significant decrease in GSH and SOD testicular levels besides a significant increase of MDA and TNF-alpha testicular levels and upregulation of testicular gene expressions of iNOS, caspase-3, and p38-MAPK in comparison to the control group. Cisplatin 9-18 tumor necrosis factor Rattus norvegicus 134-143 28686978-7 2017 Cisplatin upregulated cytokines (i.e., TNF-alpha and IL-6) and MPO, increased apoptosis, and downregulated Nrf2 and HO-1. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 39-48 28258441-10 2017 In addition, cisplatin showed a marked pro-inflammatory response as revealed by a significant increase in the tissue levels of TNF-alpha, IL-6, IL-8 and decrease in the IL-10 level. Cisplatin 13-22 tumor necrosis factor Rattus norvegicus 127-136 28258441-11 2017 Pre-treatment of curcumin reduced cisplatin-induced nephrotoxicity which was clearly evident from the reduced BUN, creatinine, TNF-alpha, IL-6 and IL-8 levels and increased albumin and IL-10 levels. Cisplatin 34-43 tumor necrosis factor Rattus norvegicus 127-136 28619064-9 2017 The animal treated with cisplatin showed a significant increase in the expression levels of the IL-1alpha (260%), TRFA2 (491%), P38 (410%), MKK4 (263%), MKK7 (412%), JNK (680%) and TNF-alpha (300%) genes compared to control group. Cisplatin 24-33 tumor necrosis factor Rattus norvegicus 181-190 29216766-6 2018 Both CSN and MTX significantly increased serum creatinine, cystatin C, and neutrophil gelatinase-associated lipocalin and kidney tissue renal malondialdehyde, inducible nitric oxide synthase, tumor necrosis factor-alpha, interleukin-18, nuclear factor-kappaB p65, cytosolic cytochrome C, and caspase-3 and significantly decreased renal total antioxidant capacity and Bcl-2/Bax ratio in rats. Cisplatin 5-8 tumor necrosis factor Rattus norvegicus 192-219 29862426-7 2018 Cisplatin induced thermal hypoalgesia and decreased rotarod performance as well as GSH serum level while increased MDA, TNF-alpha, and caspase-3 serum levels with atrophy and fragmentation of the nerve fibers with decreased expression of myelin basic protein. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 120-129 29865885-5 2018 Dunnione repressed cisplatin-induced inflammation in the kidneys as indicated by decreased TNF-alpha/IL-1beta levels, and reduced nuclear phosphorylated NF-kappaB p65. Cisplatin 19-28 tumor necrosis factor Rattus norvegicus 91-100 28282556-6 2017 Data showed that cisplatin caused elevation in serum creatinine and urea, disturbance in blood count, elevation in gene expression of tumor necrosis factor alpha, nuclear factor kappa B, interleukin-1beta, caspase-3, mitochondrial cytochrome C and apoptosis-inducing factor in renal tissue. Cisplatin 17-26 tumor necrosis factor Rattus norvegicus 134-185 27273121-6 2016 On day 10, cisplatin resulted in significant nephrotoxicity in Wistar rats with a drastic elevation of serum creatinine and BUN, a decline in the concentrations of GSH, MDA and superoxide dismutase (SOD), and an elevation in the TNF-alpha level in renal tissues. Cisplatin 11-20 tumor necrosis factor Rattus norvegicus 229-238 27667768-5 2016 On day 10, cisplatin resulted in substantial nephrotoxicity in Wistar rats with significant (p < 0.001) elevation in serum creatinine and blood urea nitrogen, decline in the concentrations of reduced glutathione and superoxide dismutase, elevation in TNF-alpha level in renal tissues. Cisplatin 11-20 tumor necrosis factor Rattus norvegicus 254-263 27600998-7 2016 Furthermore, compared with untreated control animals, cisplatin lead to significantly increased expression of Fas ligand, tumor necrosis factor-alpha (TNF-alpha), caspase-8 and Bcl-2 associated protein X apoptosis regulator (Bax), and decreased expression of anti-apoptosis regulators, BH3 interacting domain death agonist (BID) and B cell lymphoma 2 apoptosis regulator (Bcl-2). Cisplatin 54-63 tumor necrosis factor Rattus norvegicus 122-149 27600998-7 2016 Furthermore, compared with untreated control animals, cisplatin lead to significantly increased expression of Fas ligand, tumor necrosis factor-alpha (TNF-alpha), caspase-8 and Bcl-2 associated protein X apoptosis regulator (Bax), and decreased expression of anti-apoptosis regulators, BH3 interacting domain death agonist (BID) and B cell lymphoma 2 apoptosis regulator (Bcl-2). Cisplatin 54-63 tumor necrosis factor Rattus norvegicus 151-160 27424012-7 2016 Levels of TNF-alpha and IL-1beta were significantly increased in the renal tissue in cisplatin group. Cisplatin 85-94 tumor necrosis factor Rattus norvegicus 10-19 25704027-7 2015 Cisplatin increased cell death, caspase-3 cleavage, activation of MAPKs and p53, oxidative stress, and mRNA expression of TNF-alpha and TNFR1 in HK-2 cells. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 122-131 27031695-5 2016 Tangeretin also attenuated cisplatin-induced hepatic inflammatory events as indicated by suppression of tumor necrosis factor-alpha (TNF-alpha) and enhancement of interleukin-10 (IL-10). Cisplatin 27-36 tumor necrosis factor Rattus norvegicus 104-131 27031695-5 2016 Tangeretin also attenuated cisplatin-induced hepatic inflammatory events as indicated by suppression of tumor necrosis factor-alpha (TNF-alpha) and enhancement of interleukin-10 (IL-10). Cisplatin 27-36 tumor necrosis factor Rattus norvegicus 133-142 27571604-12 2016 Moreover, enalapril dose dependently inhibited cisplatin-induced inflammation (NF-kappaB/IKK-beta/IL-6/Cox-2/TNF-alpha expressions), apoptosis (increased Bcl-2 and reduced p53, cytochrome c, Bax and caspase-3 expressions, and TUNEL/DAPI positivity) and preserved the structural integrity of the kidney. Cisplatin 47-56 tumor necrosis factor Rattus norvegicus 109-118 26612737-5 2015 Cisplatin administration triggered inflammatory responses and apoptosis in rat livers and kidneys as evident by increased expression of pro-inflammatory cytokine, tumor necrosis factor- alpha (TNF-alpha) and apoptotic marker p38 mitogen-activated protein kinase (p38 MAPK) as results of overproduction of ROS. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 163-191 26612737-5 2015 Cisplatin administration triggered inflammatory responses and apoptosis in rat livers and kidneys as evident by increased expression of pro-inflammatory cytokine, tumor necrosis factor- alpha (TNF-alpha) and apoptotic marker p38 mitogen-activated protein kinase (p38 MAPK) as results of overproduction of ROS. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 193-202 26536032-4 2015 dose of cisplatin (5 mg/kg) alone or combined with pioglitazone (PPARgamma agonist), fenofibrate (PPARalpha agonist), pioglitazone plus fenofibrate, or thalidomide (Tumor necrosis factor-alpha inhibitor; TNF-alpha). Cisplatin 8-17 tumor necrosis factor Rattus norvegicus 165-192 26536032-4 2015 dose of cisplatin (5 mg/kg) alone or combined with pioglitazone (PPARgamma agonist), fenofibrate (PPARalpha agonist), pioglitazone plus fenofibrate, or thalidomide (Tumor necrosis factor-alpha inhibitor; TNF-alpha). Cisplatin 8-17 tumor necrosis factor Rattus norvegicus 204-213 26536032-5 2015 Cisplatin nephrotoxicity was evidenced by rises in renal indices of functional (blood urea nitrogen, BUN, and creatinine), inflammatory (TNF-alpha, interleukin 6, IL-6), oxidative (increased malondialdehyde, MDA, and decreased superoxide dismutase, SOD and nitric oxide metabolites, NOx), apoptotic (caspase 3), and histological (glomerular atrophy, acute tubular necrosis and vacuolation) profiles. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 137-146 26517155-12 2016 Furthermore, arjunolic acid showed dose dependent reduction in cisplatin-induced elevation in renal levels of TGF-betaR1, TGF-beta1, TNF-alpha, IL-1beta and caspases. Cisplatin 63-72 tumor necrosis factor Rattus norvegicus 133-142 27571604-13 2016 Thus, enalapril attenuated cisplatin-induced renal injury via inhibiting PARP activation and subsequent MAPKs/TNF-alpha/NF-kappaB mediated inflammatory and apoptotic response. Cisplatin 27-36 tumor necrosis factor Rattus norvegicus 110-119 25688351-10 2015 Also, nontreated cisplatin-injected rats showed significantly higher TNF-alpha and MDA levels and lower GSH level than control group. Cisplatin 17-26 tumor necrosis factor Rattus norvegicus 69-78 23712360-6 2013 The extracellular levels of HMGB1, TNF-alpha and IFN-gamma were also significantly decreased by the administration of cisplatin. Cisplatin 118-127 tumor necrosis factor Rattus norvegicus 35-44 24001946-3 2013 The nephrotoxic potential of cisplatin has been ascribed to its accumulation in the, renal tubular cells generating reactive oxygen species (ROS), activation of Bax, increased secretion of, TNFalpha and activation of certain inflammatory mediators like cytokines. Cisplatin 29-38 tumor necrosis factor Rattus norvegicus 190-198 24001946-5 2013 Pretreatment of rosiglitazone prevents cisplatin induced nephrotoxicity which was, clearly evident from the renal biochemical parameters like reduced BUN, creatinine and TNFalpha levels, and increased albumin levels, which was also supported by histopathological studies of the kidneys. Cisplatin 39-48 tumor necrosis factor Rattus norvegicus 170-178 25130312-2 2014 Cisplatin induced a significant reduction in testicular weights, plasma testosterone, and testicular reduced glutathione levels in addition to a significant elevation of testicular malondialdehyde levels and testicular gene expressions of inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), and p38 mitogen-activated protein kinase (MAPK) when compared with the control group (p < 0.05). Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 279-306 25130312-2 2014 Cisplatin induced a significant reduction in testicular weights, plasma testosterone, and testicular reduced glutathione levels in addition to a significant elevation of testicular malondialdehyde levels and testicular gene expressions of inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), and p38 mitogen-activated protein kinase (MAPK) when compared with the control group (p < 0.05). Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 308-317 25130312-5 2014 Arjunolic acid plays a significant protective role against cisplatin-induced testicular injury by attenuating oxidative stress parameters along with downregulation of iNOS, TNF-alpha, and p38-MAPK testicular expressions. Cisplatin 59-68 tumor necrosis factor Rattus norvegicus 173-182 25184746-5 2014 Fisetin treatment also significantly attenuated the cisplatin-induced IkappaBalpha degradation and phosphorylation and blocked the NF-kappaB (p65) nuclear translocation, with subsequent elevation of pro-inflammatory cytokine, TNF-alpha, protein expression of iNOS and myeloperoxidase activities. Cisplatin 52-61 tumor necrosis factor Rattus norvegicus 226-235 25228176-1 2014 OBJECTIVES: To investigate whether infliximab (Ib), an inhibitor of tumor necrosis factor alpha (TNF-alpha), prevents cisplatin (Cis)-induced nephrotoxicity. Cisplatin 118-127 tumor necrosis factor Rattus norvegicus 68-95 25228176-1 2014 OBJECTIVES: To investigate whether infliximab (Ib), an inhibitor of tumor necrosis factor alpha (TNF-alpha), prevents cisplatin (Cis)-induced nephrotoxicity. Cisplatin 118-127 tumor necrosis factor Rattus norvegicus 97-106 23353054-6 2013 Cisplatin administration also triggered inflammatory response in rat kidneys by inducing pro-inflammatory cytokine, TNF-alpha, with the increased expression of myeloperoxidase (MPO). Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 116-125 21776018-8 2011 STAT1 siRNA attenuated the increase in inflammatory mediators, such as TNF-alpha, inhibition of which protected cells from cisplatin-mediated apoptosis. Cisplatin 123-132 tumor necrosis factor Rattus norvegicus 71-80 21605616-5 2011 Rutin pretreatment prevented deteriorative effects induced by cisplatin through a protective mechanism that involved reduction of increased oxidative stress as well as caspase-3, TNF-alpha and NFkappaB protein expression levels. Cisplatin 62-71 tumor necrosis factor Rattus norvegicus 179-188 21776018-9 2011 Finally, we showed that trans-tympanic administration of etanercept, a TNF-alpha antagonist, protected against OHC damage and cisplatin-induced hearing loss. Cisplatin 126-135 tumor necrosis factor Rattus norvegicus 71-80 18001039-9 2007 A single dose of cisplatin resulted in marked inflammation (486% rise in TNF-alpha level) and oxidative stress and significantly deranged renal functions as well as renal morphology. Cisplatin 17-26 tumor necrosis factor Rattus norvegicus 73-82 20817559-7 2010 RESULTS: A single dose of cisplatin resulted in an increase in malondialdehyde, 8-isoprostane, and tumor necrosis factor-alpha levels of kidney and significantly deranged renal function (urea-N and creatinine; P < .0001). Cisplatin 26-35 tumor necrosis factor Rattus norvegicus 80-126 19356226-8 2009 RESULTS: Our data shows involvement of TNF-alpha in preventing cisplatin induced nephrotoxicity by rosiglitazone. Cisplatin 63-72 tumor necrosis factor Rattus norvegicus 39-48 18385389-3 2008 METHODS: We investigated the effects of NAC on oxidative stress and oxidation-associated signals, such as p38 mitogen-activated protein kinase (MAPK), NF-kappaB and TNF-alpha, in CDDP-induced acute renal failure (ARF) rats, in comparison to the effects of melatonin (MT), one of the physiological TNF-alpha inhibitors, and pyrrolidine dithiocarbamate (PDTC), a NF-kappaB inhibitor. Cisplatin 179-183 tumor necrosis factor Rattus norvegicus 297-306 18385389-5 2008 CDDP-triggered NF-kappaB translocation into the nucleus and TNF-alpha mRNA increase in the kidney were also inhibited in NAC-treated rats. Cisplatin 0-4 tumor necrosis factor Rattus norvegicus 60-69 15581271-8 2004 By RT-PCR analysis, the expression of TGF-beta1 and TNF-alpha mRNAs in CDDP/LPS-injected rats on day 7 was markedly increased in contrast to those in CDDP-injected rats. Cisplatin 71-75 tumor necrosis factor Rattus norvegicus 52-61 16632117-10 2006 These findings suggest that cyclic AMP protects renal tubular cells against cisplatin-induced oxidative injury by obliterating reactive oxygen species and subsequent inhibition of TNF-alpha synthesis through blockade of p38 MAPK activation. Cisplatin 76-85 tumor necrosis factor Rattus norvegicus 180-189 17516123-4 2007 We also observed a significant increase in the protein and mRNA levels of proinflammatory cytokines in both serum and cochleae of cisplatin-injected rats, which was suppressed by intraperitoneal injection of etanercept, an inhibitor of TNF-alpha. Cisplatin 130-139 tumor necrosis factor Rattus norvegicus 236-245 17516123-5 2007 Immunohistochemical studies revealed that TNF-alpha expression was mainly located in the spiral ligament, spiral limbus, and the organ of Corti in the cochleae of cisplatin-injected rats. Cisplatin 163-172 tumor necrosis factor Rattus norvegicus 42-51 17641529-7 2007 RESULTS: Cisplatin injection induced neutrophil recruitment and increased tumor necrosis factor-alpha and interleukin-1beta contents in renal cortices and outer medullae tissues. Cisplatin 9-18 tumor necrosis factor Rattus norvegicus 74-101 16632117-4 2006 Cisplatin enhanced lipid peroxidation, decreased CuZn superoxide dismutase (SOD) while enhancing MnSOD activity, and increased cellular tumor necrosis factor-alpha (TNF-alpha) content. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 136-163 16632117-4 2006 Cisplatin enhanced lipid peroxidation, decreased CuZn superoxide dismutase (SOD) while enhancing MnSOD activity, and increased cellular tumor necrosis factor-alpha (TNF-alpha) content. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 165-174 16632117-5 2006 The elevation of TNF-alpha content and cell injury induced by cisplatin were attenuated by p38 mitogen-activated protein kinase (MAPK) inhibitors including SB203580 and PD169316. Cisplatin 62-71 tumor necrosis factor Rattus norvegicus 17-26 16632117-8 2006 The in vivo acute renal injury after cisplatin injection was associated with the elevation of renal TNF-alpha content. Cisplatin 37-46 tumor necrosis factor Rattus norvegicus 100-109 16632117-9 2006 The cisplatin-induced renal injury and the increase in TNF-alpha content were reversed by NAC or beraprost. Cisplatin 4-13 tumor necrosis factor Rattus norvegicus 55-64 12684229-7 2003 RT-PCR indicated cisplatin-induced upregulation of Fas, Fas ligand, and TNF-alpha mRNAs and complete inhibition by DMTU in vitro and in vivo. Cisplatin 17-26 tumor necrosis factor Rattus norvegicus 72-81 15581271-8 2004 By RT-PCR analysis, the expression of TGF-beta1 and TNF-alpha mRNAs in CDDP/LPS-injected rats on day 7 was markedly increased in contrast to those in CDDP-injected rats. Cisplatin 150-154 tumor necrosis factor Rattus norvegicus 52-61 1638521-8 1992 These data show that TNF enhanced the platinum + WBH-mediated antitumor effect without increasing normal tissue toxicity, suggesting that TNF may increase the therapeutic efficacy of CDDP or CBDCA combined with WBH. Cisplatin 183-187 tumor necrosis factor Rattus norvegicus 21-24 1638521-2 1992 TNF (1 x 10(5) units/kg) increased the antitumor effect of both CDDP (1.5 mg/kg) + WBH (2 h at 41.5 degrees C) and CBDCA (30 mg/kg) + WBH. Cisplatin 64-68 tumor necrosis factor Rattus norvegicus 0-3 1638521-3 1992 Tumor growth delay, which was 1.9 days for CDDP + WBH and 2.7 days for CBDCA + WBH (P less than 0.01 compared to control), was significantly increased to 2.9 days with TNF + CDDP + WBH and 5.4 days with TNF + CBDCA + WBH (P less than 0.05). Cisplatin 174-178 tumor necrosis factor Rattus norvegicus 203-206 1638521-8 1992 These data show that TNF enhanced the platinum + WBH-mediated antitumor effect without increasing normal tissue toxicity, suggesting that TNF may increase the therapeutic efficacy of CDDP or CBDCA combined with WBH. Cisplatin 183-187 tumor necrosis factor Rattus norvegicus 138-141 33235694-10 2020 However, it was determined that the expressions of TNF-alpha and Caspase-3 were in mild levels in fraxin + cisplatin treatment group. Cisplatin 107-116 tumor necrosis factor Rattus norvegicus 51-60 2125975-4 1990 Cisplatin was found to up-regulate rIL-1-induced macrophage activation but inhibited the activation of macrophages with rTNF-alpha. Cisplatin 0-9 tumor necrosis factor Rattus norvegicus 120-130 2227544-6 1990 Doses of rTNF that were minimally cytotoxic resulted in significant cytotoxicity and synergy when used with optimal or suboptimal concentrations of ADR or CDDP. Cisplatin 155-159 tumor necrosis factor Rattus norvegicus 9-13 34916822-8 2021 In the CDDP-induced cognitive impairment (CICI) rats, there were remarkable increases in the brain levels of TNF-alpha, IL-6 and IL-1beta and malondialdehyde (MDA), whereas catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx) and superoxide dismutase (SOD) activities considerably decreased compared to normal control. Cisplatin 7-11 tumor necrosis factor Rattus norvegicus 109-118 34877753-7 2022 RESULTS: In the CDDP group, it is determined that statistically significant decreasing in the levels of TAS and CAT, and increasing in the levels of MDA, TOS, OSI, 8-OHdG, caspase-3, and TNF-alpha compared with control group (p < 0.05). Cisplatin 16-20 tumor necrosis factor Rattus norvegicus 187-196 34886721-9 2021 In the CDDP group, it is determined that statistically significant decreasing in the levels of TAS and CAT, and increasing in the levels of MDA, TOS, OSI, 8-OHdG, caspase-3 and TNF-alpha (p < 0.05) compared with control group. Cisplatin 7-11 tumor necrosis factor Rattus norvegicus 177-186 34635013-12 2021 The increase in pro-inflammatory cytokine (IL-1beta, IL-6 and TNF-alpha) levels caused by CDDP administration was observed to be significantly decreased in the CDDP + EP group. Cisplatin 90-94 tumor necrosis factor Rattus norvegicus 62-71 34635013-12 2021 The increase in pro-inflammatory cytokine (IL-1beta, IL-6 and TNF-alpha) levels caused by CDDP administration was observed to be significantly decreased in the CDDP + EP group. Cisplatin 160-164 tumor necrosis factor Rattus norvegicus 62-71 35563891-4 2022 This functional and confocal microscopy study shows the renal focal-segmental expression of TNFalpha after cisplatin administration in rats, predominantly of tubular localization and mostly prevented by co-administration of cilastatin. Cisplatin 107-116 tumor necrosis factor Rattus norvegicus 92-100 35507972-6 2022 It also increased cisplatin-induced decrease in BDNF, increase in TNF-alpha and decrease in reduced glutathione levels. Cisplatin 18-27 tumor necrosis factor Rattus norvegicus 66-75